Core Viewpoint - Suzhou Fengbei Biotechnology announced plans to engage in foreign exchange derivatives trading, including forward foreign exchange settlements and foreign exchange options, to mitigate risks associated with fluctuations in the foreign exchange market [1] Group 1: Business Strategy - The company and its subsidiaries intend to utilize up to $50 million (or equivalent currency) of idle funds for these transactions [1] - The trading period will not exceed 12 months, and the transaction amounts can be reused [1] Group 2: Risk Management - The company has established corresponding risk control measures, asserting that the business operations are necessary and feasible [1] - The maximum trading margin and premium will not exceed $2.5 million [1]
苏州丰倍生物：拟开展不超5000万美元外汇衍生品交易业务